Jefferies analyst Anthony Petrone's revised sum-of-the-parts analysis on Antares Pharma continues to assign a current risk-adjusted value of $8 per share. However, it ow sees upside to $18-$20, versus $15 prior, based on "strong initial feedback" on Xyosted, "longer tailwind" for Makena, larger opportunity for generic EpiPen given ongoing shortages, and earlier potential launch of generic Forteo. Early feedback from physicians and patients is positive and continues to support that 20% share capture is feasible for Xyosted over time, Petrone tells investors in a research note. He keeps a Buy rating on Antares Pharma.